Stock Events

Stock Events

OmniAb

$0.3862

23

+$0.04+10.34% Thursday 17:53

-$0.05-11.96%Thursday 20:00After hours

Statistics

Day High

0.3862

Day Low

0.34

52W High

0.3862

52W Low

0.34

Volume

1,000

Avg. Volume

-

Mkt Cap

56.15M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

17NovExpected

Q4 2024

Q1 2025

Q2 2025

Q3 2025

Q1 2026

Q2 2026

Next

-0.17

-0.13

-0.09

-0.05

Expected EPS

-0.127143

Actual EPS

N/A

Financials

-347.04%Profit Margin

Unprofitable

2021

2022

2023

2024

2025

18.67MRevenue

-64.78MNet Income

Analyst Ratings

11.00Average Price Target

The highest estimate is 11.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OABIW. It's not an investment recommendation.

Mastercard Incorporated

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a leading biotech company that competes with OmniAb in the development of monoclonal antibodies for various therapeutic areas.

Amgen is a biopharmaceutical company that competes in the discovery, development, and manufacturing of human therapeutics, including monoclonal antibodies, similar to OmniAb's focus.

Eli Lilly and Company is a competitor due to its strong focus on antibody therapies, including its efforts in immunology and oncology, areas that overlap with OmniAb's interests.

Gilead Sciences

Gilead Sciences competes with OmniAb in the biopharmaceutical field, particularly in the development of treatments that involve monoclonal antibodies for infectious diseases, among others.

Bristol-Myers Squibb

Bristol-Myers Squibb is involved in the discovery and development of innovative medicines, including monoclonal antibodies for cancer and other diseases, making it a competitor to OmniAb.

Merck & Co., Inc. competes with OmniAb through its extensive research and development in biopharmaceuticals, including therapies based on monoclonal antibodies for various diseases.

Pfizer is a global pharmaceutical company that competes with OmniAb in the development and commercialization of biopharmaceuticals, including monoclonal antibodies for a wide range of conditions.

AstraZeneca is a competitor because of its focus on the development of biopharmaceuticals, including monoclonal antibodies for the treatment of diseases in areas like oncology, which overlaps with OmniAb's focus.

Roche Holding AG competes with OmniAb through its subsidiary Genentech in the research and development of monoclonal antibody therapies, particularly in oncology and immunology.

Sanofi competes with OmniAb in the global healthcare market, particularly in the development of monoclonal antibodies for immunological diseases, an area of focus for OmniAb.

About

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Show more...

CEO

Matthew W. Foehr

Employees

89

Country

United States

ISIN

US68218J1117

Listings

0 Comments

Share your thoughts

FAQ

What is OmniAb stock price today?▼

The current price of OABIW is $0.39 USD — it has increased by +10.34% in the past 24 hours. Watch OmniAb stock price performance more closely on the chart.

What is OmniAb stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange OmniAb stocks are traded under the ticker OABIW.

What is OmniAb market cap?▼

Today OmniAb has the market capitalization of 56.15M

When is the next OmniAb earnings date?▼

OmniAb is going to release the next earnings report on November 17, 2026.

What were OmniAb earnings last quarter?▼

OABIW earnings for the last quarter are -0.05 USD per share, whereas the estimation was -0.12 USD resulting in a +58.33% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is OmniAb revenue for the last year?▼

OmniAb revenue for the last year amounts to 18.67M USD.

What is OmniAb net income for the last year?▼

OABIW net income for the last year is -64.78M USD.

How many employees does OmniAb have?▼

As of September 04, 2026, the company has 89 employees.

In which sector is OmniAb located?▼

OmniAb operates in the Health & Wellness sector.

When did OmniAb complete a stock split?▼

OmniAb has not had any recent stock splits.

Where is OmniAb headquartered?▼

OmniAb is headquartered in EMERYVILLE, United States.